In human hepatocellular carcinoma, miR-200a-3p targets dual-specificity phosphatase 6 (DUSP6) to augment cancer cell resistance to 5-fluorouracil, doxorubicin, and cisplatin (361). Here, DUSP6 is linked to cancer.